🇺🇸 FDA

Intelligence Platform

Patents

Browse 12 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 10004785

LKKTET and/or LKKTNT peptide compositions which are lyophilized or in a form capable of be

REGENERX BIOPHARMACEUTICALS, INC. · Granted Tue Jun 26 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 21 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9821030

LKKTET and/or LKKTNT peptide compositions which are lyophilized or in a form capable of be

REGENERX BIOPHARMACEUTICALS, INC. · Granted Tue Nov 21 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 16 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9585941

Eye drop formulation

REGENERX BIOPHARMACEUTICALS, INC. · Granted Tue Mar 07 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 02 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9504730

Method of achieving a thymosin beta 4 concentration in a human patient

REGENERX BIOPHARMACEUTICALS, INC. · Granted Tue Nov 29 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 24 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9056087

Methods of healing or preventing inflammation, damage and other changes that occur prior t

REGENERX BIOPHARMACEUTICALS, INC. · Granted Tue Jun 16 2015 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 11 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8716215

Method of treating or preventing tissue deterioration, injury or damage due to a neuro-, m

REGENERX BIOPHARMACEUTICALS, INC. · Granted Tue May 06 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 01 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8426365

Method of treating or preventing tissue deterioration, injury or damage due to congestive

REGENERX BIOPHARMACEUTICALS, INC. · Granted Tue Apr 23 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 18 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8399609

Treating or preventing extracellular matrix build-up

REGENERX BIOPHARMACEUTICALS, INC. · Granted Tue Mar 19 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 14 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8399412

Method of treating or preventing tissue deterioration, injury or damage due to periodontal

REGENERX BIOPHARMACEUTICALS, INC. · Granted Tue Mar 19 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 14 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8383576

LKKTET and/or LKKTNT peptide compositions which are lyophilized or in a form capable of be

REGENERX BIOPHARMACEUTICALS, INC. · Granted Tue Feb 26 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 21 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8143218

Treatment of skin, and wound repair, with thymosin beta 4

REGENERX BIOPHARMACEUTICALS, INC. · Granted Tue Mar 27 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 22 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8093214

Method of treating or preventing tissue deterioration, injury or damage due to congestive

REGENERX BIOPHARMACEUTICALS, INC. · Granted Tue Jan 10 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 05 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

granted